Isis To Speed Development Of Oral TNF-Alpha Inhibitor For Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to initiate a Phase II trial comparing oral and subcutaneous formulations of anti-TNF alpha antisense agent ISIS 104838 in mid-2005. Drug could have a chance at being the first oral TNF inhibitor on the RA market.
You may also be interested in...
Pfizer Looks To Enter Oral Anti-Thrombotic Market Through Schering AG Deal
Company in-licenses Schering AG’s preclinical oral ADP receptor antagonist line; agents are targeted for chronic use in prophylaxis of arterial thrombosis and other CV events. Pfizer has one marketed anti-thrombotic, none in clinical development.
Pozen’s Migraine Agent To Be Focus Of FDA Advisory Committee Review
Naproxen/metoclopramide combination is expected to be reviewed by the Peripheral & Central Nervous System Drugs Advisory Committee May 4. Potential risk of tardive dyskinesia is expected to be discussed. FDA deemed MT-100 “not approvable” earlier this year.
Takeda Files Actos/Metformin Combination Actoplus Met For Type 2 Diabetes
NDA submission of pioglitazone/metformin combo marks beginning of Takeda’s expansion in the U.S. diabetes market; the firm has insulin resistance-improving agents in Phase II and Phase III.